Global Circulating Tumor Cells Market Segments 2024, Forecast To 2033
5 Mar, 2024
The circulating tumor cells market grew rapidly, reaching $10.79 billion in 2023 and $12.21 billion in 2024, with a 13.1% CAGR. Historical growth is linked to cancer incidence, liquid biopsy emergence, and regulatory support. Expected to grow to $19.45 billion in 2028, the forecast period highlights point-of-care CTC testing, microfluidics adoption, and rare cancer focus, with trends like liquid biopsy for cancer monitoring and AI integration shaping the market.
Global Circulating Tumor Cells Market Key Driver
The circulating tumor cells market is poised for growth due to the growing incidence of cancer. Circulating tumor cells play a crucial role in the early detection and diagnosis of cancer. In 2021, it was estimated that 1.9 million new cancer cases would be diagnosed in the United States, leading to 608,570 cancer-related deaths. As the incidence of cancer continues to rise, the demand for circulating tumor cells for diagnostic purposes will increase.
Get A Free Sample Of The Global Circulating Tumor Cells Market ReportGlobal Circulating Tumor Cells Market Segments
The circulating tumor cells market covered in this report is segmented –
1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems
2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis
3) By Specimen: Blood, Bone Marrow, Other Body Fluids
4) By Application: Clinical Or Liquid Biopsy, Research
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the circulating tumor cells market in 2023. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Circulating Tumor Cells Industry Players
Precision Medicine Group LLC; Bio-Techne Corporation; BIOCEPT Inc.; Creativ MicroTech Inc.; Fluxion Biosciences Inc.; Ikonisys Inc.; Qiagen N.V.; ScreenCell SAS; STEMCELL Technologies Inc.; Sysmex Corporation; Aviva Biosciences Corporation; LungLife AI Inc.; Miltenyi Biotec GmbH; Menarini Silicon Biosystems S.p.A.; Canopus Bioscience Ltd.; IVDiagnostics Inc.; BioFluidica Inc.; Biolidics Limited; Rarecells Diagnostics SAS; LineaRx Inc.; Thermo Fisher Scientific Inc.; Greiner Bio-One International GmbH; Stanford Research Institute International; Agilent Technologies Inc.; Resolution Bioscience Inc.; Cynvenio Biosystems Inc.; ApoCell Inc.; Clearbridge BioMedics Pte. Ltd.; Celsee Inc.; RareCyte Inc.; On-chip Biotechnologies Co. Ltd.
Get The Full Global Circulating Tumor Cells Market Report
AIOps Circulating Tumor Cells Market Overview
Circulating tumor cells refer to solid tumor-derived cells that have shed from the primary tumor and are extravasated into the blood circulation system. They are used as a tool to diagnose and prognosis of cancer.
Circulating Tumor Cells Global Market Report 2023 provides data on the global circulating tumor cells market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The circulating tumor cells market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.